scholarly journals Prognostic Value of MACC1 in Digestive System Neoplasms: A Systematic Review and Meta-Analysis

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Zhenzhen Wu ◽  
Rui Zhou ◽  
Yuqi Su ◽  
Li Sun ◽  
Yulin Liao ◽  
...  
Keyword(s):  
Systematic Review ◽  
Survival Data ◽  
Prognostic Value ◽  
Digestive System ◽  
Meta Analysis ◽  
Anatomic Structure ◽  
Free Survival ◽  
Effect Measure ◽  
Digestive System Neoplasms ◽  
Individualized Management

Metastasis associated in colon cancer 1 (MACC1), a newly identified oncogene, has been associated with poor survival of cancer patients by multiple studies. However, the prognostic value of MACC1 in digestive system neoplasms needs systematic evidence to verify. Therefore, we aimed to provide further evidence on this topic by systematic review and meta-analysis. Literature search was conducted in multiple databases and eligible studies analyzing survival data and MACC1 expression were included for meta-analysis. Hazard ratio (HR) for clinical outcome was chosen as an effect measure of interest. According to our inclusion criteria, 18 studies with a total of 2,948 patients were identified. Pooled HRs indicated that high MACC1 expression significantly correlates with poorer OS in patients with digestive system neoplasms (HR = 1.94; 95% CI: 1.49–2.53) as well as poorer relapse-free survival (HR = 1.94, 95% CI: 1.33–2.82). The results of subgroup studies categorized by methodology, anatomic structure, and cancer subtype for pooled OS were all consistent with the overall pooled HR for OS as well. No publication bias was detected according to test of funnel plot asymmetry and Egger’s test. In conclusion, high MACC1 expression may serve as a prognostic biomarker to guide individualized management in clinical practice for digestive system neoplasms.

scholarly journals Prognostic Value of NME1 (NM23-H1) in Patients with Digestive System Neoplasms: A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2016 ◽  
Vol 11 (8) ◽  
pp. e0160547 ◽  
Author(s):  
Wei Han ◽  
Chun-tao Shi ◽  
Fei-yun Cao ◽  
Fang Cao ◽  
Min-bin Chen ◽  
...  
Keyword(s):  
Systematic Review ◽  
Prognostic Value ◽  
Digestive System ◽  
Meta Analysis ◽  
Digestive System Neoplasms

scholarly journals The Prognostic value of the Fibrinogen to pre-albumin ratio in malignant tumors of the digestive system: a systematic review and meta-analysis

2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Baibei Li ◽  
Huachu Deng ◽  
Ziyan Zhou ◽  
Bo Tang
Keyword(s):  
Systematic Review ◽  
Prognostic Value ◽  
Digestive System ◽  
Malignant Tumors ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Poor Overall Survival ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Albumin Ratio

Abstract Background In recent years, the Fibrinogen to pre-albumin ratio (FPR) has been reported in many studies to be significantly associated with the prognosis of various cancers. This systematic review and meta-analysis aimed to investigate the prognostic value of FPR in malignant tumors of the digestive system based on available evidence. Methods The relevant articles published before July 1, 2021, were systematically retrieved from electronic databases to evaluate the effect of Fibrinogen to pre-albumin ratio (FPR) on the prognosis of patients with malignant digestive system tumors and calculate the hazard ratio (HR) and the corresponding 95% confidence interval (CI). Result Thirteen articles, all from China, including 15 cohort studies and a total of 5116 cases, were included in this study. A high FPR was associated with poor overall survival (HR = 1.88, 95%CI 1.53–2.32, P < 0.001), recurrence-free survival (HR = 2.29, 95%CI 1.91–2.76, P < 0.001), progression-free survival (HR = 1.96, 95%CI: 1.33–2.90, P = 0.001), complications (HR = 1.78, 95%CI: 1.06–3.00, P = 0.029), disease-free survival (HR = 1.46, 95%CI: 1.08–1.97, P = 0.013) was significantly associated with cancer-specific survival (HR = 1.44, 95%CI: 1.15–1.79, P = 0.001). Even though intergroup differences were present, FPR was strongly associated with overall and relapse-free survival, and sensitivity analysis suggested that our results were stable. Conclusion FPR can be used as a valuable indicator to predict the prognosis of patients with malignant digestive system tumors.

Predictive Prognostic Value of Tissue-Based MicroRNA Expression in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-analysis

2018 ◽  
Vol 97 (7) ◽  
pp. 759-766 ◽  
Author(s):  
G. Troiano ◽  
F. Mastrangelo ◽  
V.C.A. Caponio ◽  
L. Laino ◽  
N. Cirillo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Mirna Expression ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Free Survival ◽  
Disease Free

Oral squamous cell carcinoma (OSCC) is a common type of cancer characterized by a low survival rate, mostly due to local recurrence and metastasis. In view of the importance of predicting tumor behavior in the choice of treatment strategies for OSCC, several studies have attempted to investigate the prognostic value of tissue biomarkers, including microRNA (miRNA). The purpose of this study was to perform a systematic review and meta-analysis to evaluate the relationship between miRNA expression and survival of OSCC patients. Studies were identified by searching on MEDLINE/PubMed, SCOPUS, Web of Science, and Google Scholar. Quality assessment of studies was performed with the Newcastle-Ottawa Scale. Data were collected from cohort studies comparing disease-free survival and overall survival in patients with high miRNA expression compared to those with low expression. A total of 15 studies featuring 1,200 OSCC samples, predominantly from Asia, met the inclusion criteria and were included in the meta-analysis. Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b). The pooled hazard ratio values (95% confidence interval) related to different miRNA expression for overall survival and disease-free survival were 2.65 (2.07–3.39) and 1.95 (1.28–2.98), respectively. The results of this meta-analysis revealed that the expression levels of specific miRNAs can robustly predict prognosis of OSCC patients.

scholarly journals Prognostic value of miR17-92 family in patients with digestive system cancers: a systematic review and meta-analysis

2019 ◽  
Vol Volume 11 ◽  
pp. 1043-1058
Author(s):  
Xiaoyun Zhang ◽  
Shijie Zhang ◽  
Qin He ◽  
Xiaojuan Gao ◽  
Lijun Yang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Prognostic Value ◽  
Digestive System ◽  
Meta Analysis

scholarly journals Prognostic Impact of Memory CD8(+) T Cells on Immunotherapy in Human Cancers: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Yao Jin ◽  
Aili Tan ◽  
Jia Feng ◽  
Zexi Xu ◽  
Peiwei Wang ◽  
...  
Keyword(s):  
Systematic Review ◽  
T Cells ◽  
Cancer Patients ◽  
Cd8 T Cells ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Prognostic Impact ◽  
Free Survival ◽  
Memory Cd8 T Cells

ObjectiveThe objective of this systematic review and meta-analysis was to determine the prognostic value of memory CD8(+) T cells in cancer patients with immunotherapy.MethodsEMBASE, MEDLINE (PubMed), and Web of Science databases were searched to identify suitabile articles published before March 2021. Risk of bias on the study level was assessed using the Cochrane Bias Risk Assessment Tool. The hazard ratios (HRs) and 95% confidence intervals (CIs) of pooled progression-free survival (PFS) and overall survival (OS) were calculated using RevMan 5.4 to evaluate the prognostic impact of memory CD8(+) T cells.ResultsIn total, nine studies were included in the final analysis. High levels of memory CD8(+) T cells were significantly closely correlated with better progression-free survival (PFS) and overall survival (OS) of cancer patients with immunotherapy (PFS, HR 0.64, 95% CI 0.53–0.78; OS, HR 0.37, 95% CI 0.21–0.65). Memory CD8(+) T cells still have significant prognostic value in cancer patients given immunotherapy alone after excluding of other interfering factors such as chemotherapy, radiotherapy, and targeted therapy (PFS, HR 0.65, 95% CI 0.48–0.89; OS, HR 0.23, 95% CI 0.13–0.42). However, high memory CD8(+) T cells levels did not correspond to a longer PFS or OS in cancer patients with non-immunotherapy (PFS, HR 1.05, 95% CI 0.63–1.73; OS, HR 1.29, 95% CI 0.48–3.48). Thus, memory CD8(+) T cells might be a promising predictor in cancer patients with immunotherapy.ConclusionsThe host’s overall immune status, and not only the tumor itself, should be considered to predict the efficacy of immunotherapy in cancer patients. This study is the first to show the significant prognostic value of memory CD8(+) T cells in immunotherapy of cancer patients through systematic review and meta-analysis. Thus, the detection of memory CD8(+) T cells has a considerable value in clinical practice in cancer patients with immunotherapy. Memory CD8(+) T cells may be promising immunotherapy targets.

scholarly journals Prognostic Value of CD166 Expression in Cancers of the Digestive System: A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2013 ◽  
Vol 8 (8) ◽  
pp. e70958 ◽  
Author(s):  
Chao Ni ◽  
Zhigang Zhang ◽  
Xiaotao Zhu ◽  
Yang Liu ◽  
Dihong Qu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Prognostic Value ◽  
Digestive System ◽  
Meta Analysis ◽  
System A

scholarly journals Prognostic Value of S100P Expression in Patients With Digestive System Cancers: A Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Bi-Xia Liu ◽  
Chao-Tao Tang ◽  
Xi-Jian Dai ◽  
Ling Zeng ◽  
Fei Cheng ◽  
...  
Keyword(s):  
Gastrointestinal Tract ◽  
Prognostic Value ◽  
Digestive System ◽  
Meta Analysis ◽  
Clinical Stage ◽  
Cochrane Library ◽  
High Morbidity ◽  
Tumor Type ◽  
Advanced Clinical Stage ◽  
Anatomic Structure

BackgroundDigestive system cancers (DSCs) are associated with high morbidity and mortality. S100P has been reported as a prognostic biomarker in DSCs, but its prognostic value remains controversial. Accordingly, we conducted a meta-analysis to investigate whether S100P is correlated with overall survival (OS) of patients with DSCs. The relationship between S100P and clinicopathological features was also evaluated.MethodsWe systematically searched PubMed, Embase, Web of Science and Cochrane Library for eligible studies up to January 2020. In total, 16 publications with 1,925 patients were included.ResultsS100P overexpression was associated with poor OS of patient with DSCs (HR=1.54, 95% CI: 1.14–2.08, P=0.005). When stratified by anatomic structure, S100P overexpression was associated with poor prognosis in non-gastrointestinal tract cancers (HR=1.98, 95% CI: 1.44–2.72, P&lt;0.001) but not in gastrointestinal tract cancers (HR=1.09, 95% CI: 0.66–1.81, P=0.727). When stratified by tumor type, S100P overexpression predicted poor OS in cholangiocarcinoma (HR=2.14, 95% CI: 1.30–3.50, P=0.003) and hepatocellular carcinoma (HR=1.91, 95% CI: 1.22–2.99, P =0.005) but not in gastric cancer (HR=0.97, 95% CI: 0.65–1.45, P=0.872), colorectal cancer (HR=1.18, 95% CI: 0.32–4.41, P=0.807), gallbladder cancer (HR=1.40, 95% CI: 0.84-2.34, P=0.198), and pancreatic cancer (HR=1.92, 95% CI: 0.99–3.72, P=0.053). Furthermore, high S100P expression was significantly associated with distant metastasis (OR=3.58, P=0.044), advanced clinical stage (OR=2.03, P=0.041) and recurrence (OR=1.66, P=0.007).ConclusionS100P might act as a prognostic indicator of non-gastrointestinal tract cancers.

scholarly journals The Prognostic Value of CD206 in Solid Malignancies: A Systematic Review and Meta-Analysis

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3422
Author(s):  
Jens M. Debacker ◽  
Odrade Gondry ◽  
Tony Lahoutte ◽  
Marleen Keyaerts ◽  
Wouter Huvenne
Keyword(s):  
Systematic Review ◽  
Prognostic Value ◽  
Negative Impact ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Prognostic Impact ◽  
Free Survival ◽  
Meta Analyses ◽  
Tumor Types

An increased presence of CD206-expressing tumor associated macrophages in solid cancers was proposed to be associated with worse outcomes in multiple types of malignancies, but contradictory results are published. We performed a reproducible systematic review and meta-analysis to provide increased evidence to confirm or reject this hypothesis following the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. The Embase, Web of Science, and MEDLINE-databases were systematically searched for eligible manuscripts. A total of 27 papers studying the prognostic impact of CD206 in 14 different tumor types were identified. Meta-analyses showed a significant impact on the overall survival (OS) and disease-free survival (DFS). While no significant differences were revealed in progression-free survival (PFS) and disease-specific survival (DSS), a shift towards negative survival was correlated with increased CD206-expresion. As a result of the different tumor types, large heterogeneity was present between the different tumor types. Subgroup analysis of hepatocellular carcinoma and gastric cancers revealed no heterogeneity, associated with a significant negative impact on OS in both groups. The current systematic review displays the increased presence CD206-expressing macrophages as a significant negative prognostic biomarker for both OS and DFS in patients diagnosed with solid cancers. Because a heterogenous group of tumor types was included in the meta-analysis, the results cannot be generalized. These results can, however, be used to further lead follow-up research to validate the specific prognostic value of CD206 in individual tumor types and therapeutic approaches.

Sign in / Sign up

Export Citation Format

Share Document